Slone Partners Places Will Geist as Chief Operating Officer at Quanterix

Share Article

Geist brings operational experience to Quanterix as company scales to support rapid growth.

Quanterix
“Will Geist is an extraordinarily talented and accomplished executive with an impressive track record of success in operations, sales, marketing, and business development leadership roles,” said Slone Partners CEO Leslie Loveless.

Slone Partners, a nationwide executive search firm for life science, biotechnology, and diagnostics companies, has announced the placement of Will Geist as Chief Operating Officer (COO) at Quanterix Corporation. In his new role, Geist will build on Quanterix’ track record of strong execution as the company expands globally and continues to disrupt pharmaceutical development and diagnostics research.

Geist brings more than 25 years of experience to Quanterix, most recently serving as Vice President and General Manager for two of Thermo Fisher Scientific’s largest business units – Protein and Cell Analysis (PCA), and qPCR. He also served a key leadership role in Thermo Fisher Scientific’s Biosciences Division COVID-19 Task Force. Prior to joining Thermo Fisher Scientific, Geist held several other top leadership titles, including Vice President of Sales, Marketing and Business Development at QIAGEN’s Quanta BioSciences.

“Will Geist is an extraordinarily talented and accomplished executive with an impressive track record of success in operations, sales, marketing, and business development leadership roles,” said Slone Partners CEO Leslie Loveless. “He will be a welcome addition to the very strong Quanterix executive team at an important time in the company’s evolution.”

“Quanterix is experiencing strong momentum across numerous digital biomarker platforms supporting drug development and non-invasive, early disease diagnostics research,” said Kevin Hrusovsky, Chairman, Chief Executive Officer and President, Quanterix. “We are fortunate to attract Will into Quanterix at this important time given his wealth of operating experience and track record for growing revenue and profitability, both commercially and operationally.”

“I am very excited to join Quanterix during this phase of growth and expansion,” said Geist. “I have long admired the company’s mission and welcome the opportunity to further operationalize and scale the innovation that Quanterix continues to achieve as part of its vision for precision health.”

Geist holds a B.A. in Biology from Dartmouth College.

ABOUT SLONE PARTNERS
Slone Partners delivers the leaders who build amazing and diverse life sciences organizations – People Are Our Science®. Founded in 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established biotech, diagnostics, research tools, healthcare, precision medicine, CRO, and laboratory services companies. With coast-to-coast presence in the most active healthcare industry hubs of Boston, San Francisco, New York, Los Angeles, San Diego, Austin, Research Triangle Park NC, and Washington DC, Slone Partners uniquely and precisely provides an array of executive search and advisory services, including diversity, equity, and inclusion strategy, to innovative life sciences companies. To learn more about Slone Partners’ value proposition and processes, visit http://www.slonepartners.com or call 888.784.3422.

ABOUT QUANTERIX CORPORATION
Founded in 2007, Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. For additional information, please visit https://www.quanterix.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Doug Gavel
Visit website